Posted by Michael Wonder on 29 Oct 2019
In generic drug plants in China and India, data falsification is still a problem
29 October 2019 - As the generic drug industry faces allegations of data manipulation, headlines about carcinogen-tainted blood pressure medicine, and an intensifying probe by the House Energy and Commerce Committee, whose health subcommittee is holding a hearing on Wednesday on safeguarding our global drug supply, generic drug industry lobbyists are fighting back.
They claim that low-cost drug makers operating overseas — where the majority of our generic drugs are made — follow the same intricate rules as U.S. based drug makers.
They argue that instances of manufacturing fraud or negligent practices are a thing of the past, having ended largely in 2013 when India’s largest drug company, Ranbaxy, pleaded guilty in the United States to seven felonies related to falsifying manufacturing data.
